Hobert Judith A, Dawson Glyn
Committee on Molecular Metabolism and Nutrition, Biological Sciences Division, University of Chicago, Chicago, IL 60637, USA.
Biochim Biophys Acta. 2006 Oct;1762(10):945-53. doi: 10.1016/j.bbadis.2006.08.004. Epub 2006 Aug 16.
Historically, many different therapies have been assessed for their ability to alter disease progression of the Neuronal Ceroid Lipofuscinoses (NCLs). While some treatments have lead to minor improvements, none have been able to arrest disease progression or improve the quality or duration of life. Presently, many new therapeutic strategies, such as chaperone therapy, enzyme replacement therapy, gene therapy, and stem cell therapy, are being investigated for their ability to alter the disease course of the NCLs. This review summarizes previous studied therapies, discusses those currently being evaluated and examines possibilities for future therapies for the treatment of patients with NCL.
从历史上看,人们已经评估了许多不同疗法改变神经元蜡样脂褐质沉积症(NCLs)疾病进展的能力。虽然一些治疗方法带来了轻微改善,但没有一种能够阻止疾病进展或改善生活质量或寿命。目前,许多新的治疗策略,如伴侣蛋白疗法、酶替代疗法、基因疗法和干细胞疗法,正在研究其改变NCLs病程的能力。本综述总结了先前研究的疗法,讨论了目前正在评估的疗法,并探讨了未来治疗NCL患者的疗法可能性。